Skip to main content
Clinical Trials/NCT06141785
NCT06141785
Recruiting
N/A

Early Nutritional Intervention to Prevent Malnutrition in Patients With Cancer Receiving Palliative Chemotherapy in an Outpatient Setting

Gødstrup Hospital1 site in 1 country200 target enrollmentJune 1, 2024

Overview

Phase
N/A
Intervention
Not specified
Conditions
Nutritional Intervention
Sponsor
Gødstrup Hospital
Enrollment
200
Locations
1
Primary Endpoint
Body weight
Status
Recruiting
Last Updated
4 months ago

Overview

Brief Summary

The goal of this intervention study is to study the effect of nutritional interventions in patients with cancer receiving palliative chemotherapy. The main question it aims to answer is: Does early nutritional interventions affect body weight, quality of life, survival, muscle mass, performance status, physical function, nutritional risk and treatment tolerance in patients with cancer receiving palliative chemotherapy? Researchers will compare patients receiving the intervention to a historical control cohort following current clinical practice.

Detailed Description

Background 30-50% of patients with cancer are malnourished, resulting in poorer prognosis, increased toxicities, reduced quality of life, and reduced physical function. Nevertheless, cancer-related malnutrition remains largely unrecognized and undertreated in clinical practice. Aim To examine the effect of an early individualised nutritional intervention on body weight, quality of life, survival, muscle mass, performance status, physical function, nutritional risk, and treatment tolerance in patients with cancer receiving palliative chemotherapy. Methods An intervention study with a historical control cohort. Participants are newly diagnosed patients with lung, pancreatic, ovarian, or colorectal cancers recruited at initiation of palliative chemotherapy. The control group followed current clinical practice. The intervention group receives an individualised nutritional intervention delivered by a clinical dietitian from treatment initiation and throughout the treatment trajectory. The intervention is tailored to the participant's nutritional needs, food preferences, nutrition impact symptoms, and smell- and taste disorders. The primary endpoint is change in body weight. Secondary endpoints include quality of life, survival, muscle mass, performance status, physical function, nutritional risk, and treatment tolerance. Data are collected at baseline and after 12 and 24 weeks. Perspectives The project will provide new knowledge on the effects of individualised nutritional interventions for patients with cancer receiving palliative chemotherapy, and the potential to improve quality of life, treatment tolerance, and survival.

Registry
clinicaltrials.gov
Start Date
June 1, 2024
End Date
January 29, 2027
Last Updated
4 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Gødstrup Hospital
Responsible Party
Principal Investigator
Principal Investigator

Kirstine Guld Frederiksen

Principal investigator

Gødstrup Hospital

Eligibility Criteria

Inclusion Criteria

  • patients who are newly diagnosed with lung, colorectal, ovarian, or pancreatic cancer.
  • patients treated with first-line palliative chemotherapy
  • patients who are Danish speaking
  • patients ≥18 years of age
  • patients who are cognitive well-functioning

Exclusion Criteria

  • Patients not using electronic mail
  • patients with dementia
  • patients not able to comply with the study protocol

Outcomes

Primary Outcomes

Body weight

Time Frame: baseline, week 12 (±2 weeks), week 24 (±2 weeks)

Change in body weight in kilogram

Secondary Outcomes

  • Hand grip strength(baseline, week 12 (±2 weeks), week 24 (±2 weeks))
  • Muscle mass(baseline and week 24 (±2 weeks))
  • Nutritional Risk(baseline, week 12 (±2 weeks), week 24 (±2 weeks))
  • Survival(one year after initiation)
  • Self reported Quality of life(baseline, week 12 (±2 weeks), week 24 (±2 weeks))
  • Performance status(baseline, week 12 (±2 weeks), week 24 (±2 weeks))
  • Duration of chemotherapy(week 24 (±2 weeks))
  • Postponements in chemotherapy treatment(week 12 (±2 weeks), week 24 (±2 weeks))
  • Timed up and go(baseline, week 12 (±2 weeks), week 24 (±2 weeks))
  • Dose intensity(baseline, week 12 (±2 weeks), week 24 (±2 weeks))
  • Chemotherapy(week 12 (±2 weeks), week 24 (±2 weeks))

Study Sites (1)

Loading locations...

Similar Trials